USFDA designates Zydus’ Usnoflast an orphan drug for ALS treatment EP News Bureau Jan 23, 2025 Usnoflast (ZYIL1) is a novel, oral small-molecule NLRP3 inhibitor. It has been studied in several pre-clinical models of…
Zydus receives USFDA approval to conduct Phase II(b) clinical trial for Usnoflast, a novel oral… EP News Bureau Jan 20, 2025 This study consists of a 36-week treatment phase, followed by a 16-week open-label extension. The change in ALSFRS-R total score…
